Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

Abstract: The invention relates to compounds of formula (I). where R, R1, R2, n, A and Cy have the meanings indicated in the description. The compounds of formula (I) are Nurr-1 modulators.

Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

Abstract: The present invention relates to a compound derived from indole, especially a therapeutically useful compound, characterized in that it is selected from compounds of formula (I) in which R1 represents a halogen or a trifluoromethyl group, R2 represents a hydrogen atom or a C1-C4 alkyl group, R3 represents an isopropyl (1-methylethyl) group or a tert-butyl (1,1-dimethylethyl) group and n=3 or 4 and pharmaceutically acceptable salts of said compounds of formula (I). Application: Treatment of neurodegenerative diseases and more particularly of Parkinson's disease.

Abstract: The present invention relates to compounds of formula: in which A, Cy, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the description. The compounds of the invention are modulators of the NURR-1 nuclear receptors.

Abstract: Indole compounds corresponding to the formula (I): as defined in the claims, pharmaceutically acceptable addition salts of such compounds, pharmaceutical compositions containing such compounds, the process for their preparation, and their use as pharmacologically active substances, especially in the treatment of hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, diabetes, endothelial dysfunction, cardiovascular disease, inflammatory disease and neurodegeneration.

Abstract: The present invention relates to compounds of formula: in which A, Cy, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the description. The compounds of the invention are modulators of the NURR-1 nuclear receptors.

Abstract: Compounds derived from indole, notably useful in therapeutics, selected from: i) the compounds of formula: and ii) the pharmaceutically acceptable salts of the compounds of formula (I); in which R1, R2, R3, R4, R5, R6, R8, R9 and Cy have defined meanings, and the use of such compounds in pharmaceuticals for the treatment of neurodegenerative diseases, particularly Parkinson's disease.

Abstract: The present patent application concerns compounds of formula (I) with R1 and R2 taken together with the nitrogen atom to which they are attached, form a mono or bicyclic saturated nitrogen-containing ring; their preparation and their use as a H3 receptor ligand for treating e.g. CNS disorders like Alzheimer's disease.

Abstract: The present patent application concerns new compounds of formula (I) with R1 and R2 taken together with the nitrogen atom to which they are attached, form a saturated nitrogen-containing ring, A is a saturated C1-4 alkylene and B a C3-4 alkylene or alkenylene chain; their preparation and their use as a H3 receptor ligand for treating e.g. CNS disorders like Alzheimer's disease.

Abstract: The present invention relates to a compound derived from indole, especially a therapeutically useful compound, characterized in that it is selected from compounds of formula (I) in which R1 represents a halogen or a trifluoromethyl group, R2 represents a hydrogen atom or a C1-C4 alkyl group, R3 represents an isopropyl (1-methylethyl) group or a tert-butyl (1,1-dimethylethyl) group and n=3 or 4 and pharmaceutically acceptable salts of said compounds of formula (I). Application: Treatment of neurodegenerative diseases and more particularly of Parkinson's disease.

Abstract: Indole compounds corresponding to the formula (I): as defined in the claims, pharmaceutically acceptable addition salts of such compounds, pharmaceutical compositions containing such compounds, the process for their preparation, and their use as pharmacologically active substances, especially in the treatment of hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, diabetes, endothelial dysfunction, cardiovascular disease, inflammatory disease and neurodegeneration.

Abstract: Indole compounds corresponding to the formula (I): as defined in the claims, pharmaceutically acceptable addition salts of such compounds, pharmaceutical compositions containing such compounds, the process for their preparation, and their use as pharmacologically active substances, especially in the treatment of hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, diabetes, endothelial dysfunction, cardiovascular disease, inflammatory disease and neurodegeneration.

Abstract: A method of activating PPAR receptors in a subject, said method comprising administering to said subject an effective PPAR receptor activating amount of a pyrrolopyridine compound corresponding to formula (I): wherein R, R1, R2, R3, R4, X, Ar and n have defined meanings, or a pharmaceutically acceptable salt thereof, particularly as part of the treatment of a disorder or disease state selected from the group consisting of atherosclerosis, myocardial infarction, hypertension, and cerebral vascular disease.

Abstract: The present patent application concerns new compounds of formula (I): displaying agonistic activity at sphingosine-1-phosphate (S1P) receptors, their process of preparation and their use as immunosuppressive agents.

Abstract: A method of activating PPAR receptors in a subject, said method comprising administering to said subject an effective PPAR receptor activating amount of a pyrrolopyridine compound corresponding to formula (I): wherein R, R1, R2, R3, R4, X, Ar and n have defined meanings, or a pharmaceutically acceptable salt thereof, particularly as part of the treatment of a disorder or disease state selected from the group consisting of atherosclerosis, myocardial infarction, hypertension, and cerebral vascular disease.

Abstract: Pyrrolopyridine compounds corresponding to formula (I): as defined in the claims, pharmaceutically acceptable salts thereof, the process for preparing such compounds, pharmaceutical compositions containing such compounds, and their use as pharmacologically active substances, especially in the treatment of hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, diabetes, endothelial dysfunction, cardiovascular diseases, inflammatory diseases and neurodegenerative diseases.